Mark Heinen - 30 Nov 2022 Form 4 Insider Report for Better Therapeutics, Inc.

Role
Head of Finance and Interim Chief Financial Officer
Signature
/s/ Mark Heinen
Issuer symbol
BTTX on OTC
Transactions as of
30 Nov 2022
Net transactions value
+$19,512
Form type
4
Filing time
02 Dec 2022, 15:15:52 UTC
Previous filing
14 Sep 2022
Next filing
21 Apr 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Award $19,512 +15,723 +22% $1.24 85,723 30 Nov 2022 Direct F1
holding BTTX Common Stock 2,281 30 Nov 2022 By daughter
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Better Therapeutics, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

Remarks:

Head of Finance and Interim Chief Financial Officer